Endpoints News
FDA issues warning for topical hair loss treatment Read in browser
Endpoints News
Thursday, 24 April 2025
Thank you for reading, dupa dupackia!
basic
UPGRADE
Taking the next steps with your drug in Japan - Register Now
Developing a drug and want to enter the Japanese market? Join Endpoints and senior Japanese leaders and they break down the regulatory and pricing dynamics behind one of the world’s top pharma markets. Get your spot today.
The potential of all-AI labs
Picture this: A chemist, biologist and computer scientist are working together in a lab. But in this case, they’re all AI agents trained on reams of papers and data, working in a virtual lab run by an AI principal investigator whose job is to herd its virtual colleagues in meetings and come up with an answer to a human-set agenda. 
The virtual lab has great potential for speeding up and scaling drug discovery and other types of scientific research, investor Morgan Cheatham told me. It’s still a pretty new concept with the chance for a “really large business to be built” around it, he said. 
On Thursday, Cheatham joined billionaire Jim Breyer’s family office Breyer Capital as a partner and its head of healthcare and life sciences, where he plans to continue investing in early stage health tech ideas spanning therapeutics, diagnostics, software and services. He’ll be keeping some relationships he’s built in his last job at Bessemer Venture Partners as the two firms co-invested in several companies.
“I really see myself as this translator between these worlds of clinical medicine, computation and research and investment,” Cheatham said. 
- Ngai
Here’s what’s new
Eli Lilly sues four telehealth companies selling compounded tirzepatide
Just a few weeks af­ter Eli Lil­ly sued two large com­pound­ing phar­ma­cies, the phar­ma gi­ant on Wednes­day filed law­suits against four tele­health com­pa­nies over their sale of com­pound­ed ver­sions of the GLP-1 obe­si­ty drug tirzepatide.
Telenutrition startup Nourish raises $70M
The startup has reached prof­itabil­i­ty a lit­tle more than a year af­ter its last raise as food as med­i­cine companies get a boost un­der the Trump ad­min­is­tra­tion.
The tariff question

We're looking at how healthcare companies address tariffs in their earnings calls over the next few weeks. How do you think tariffs will impact health insurers and providers (if at all)?
Email me
This week in health Тech
The FDA on Tuesday issued a warning about topical finasteride, a hair loss medication that’s often prescribed by online health services like Hims and Keeps. Finasteride is approved by the FDA in an oral form, not a topical one. There were 32 cases of adverse events reported between 2019 and 2024, the FDA said, and “Some consumers expressed they became very depressed, suffering with pain and their lives were ruined because of these symptoms,” which included erectile dysfunction, anxiety and brain fog.

Ascertain, a startup using AI agents to assist care teams, raised $10 million. Deerfield Management led the round, and New York health system Northwell Health made a strategic investment. 
Hinge Health on Tuesday said that it’s now working with Cigna, to offer its virtual physical therapy services to the health plan’s self-insured employer clients. These types of relationships with health plans make up a significant amount of Hinge’s revenue, according to the company’s S-1 filing.
John Carroll
Editor & Founder
Arsalan Arif
Publisher & Founder
Igor Yavych
Architect & Founder
Valentin Manov
Creative Director
Ryan McRae
Chief Revenue Officer
Amanda Florez
Chief of Staff
Drew Armstrong
Executive Editor
Liam Chua
Chief Technical Officer
Jaimy Lee
Deputy Editor
Lydia R. Pflanzer
Deputy Editor
Zachary Brennan
Senior Editor
Max Gelman
Senior Editor
Julie O'Meara
Executive Director, Brand Partnerships
Melissa Nazzaro
Executive Director, Brand Partnerships
James Cherrick
Controller
and many